
NCD Immuno-Pharma Private Limited
About NCD Immuno-Pharma Private Limited
Data last updated:
NCD Immuno-Pharma Private Limited is a private limited company based in Kolkata, West Bengal, India. It operates in the drug formulation and development segment of the pharmaceuticals sector. It was incorporated on 29 March 2022.
The company is registered with the Registrar of Companies (ROC), Kolkata, under CIN U24231WB2022PTC252589. Its GSTIN is 19AAICN1517G1ZI (West Bengal).
The company has an authorised share capital of ₹10 Lakh and a paid-up capital of ₹4 Lakh. It is led by directors Sandip Kumar Goswami (Managing Director) and Arijit Das.
Its last annual general meeting (AGM) was held on 30 September 2025, and its latest financial statements are for the year ended 31 March 2025. The registered office is at Room No. 501 5th Floor 'Sri Sai Plaza' Building 89 A.J.C. Bose Road, Kolkata, West Bengal, India – 700014.
As per the financials filed for FY 2025, the company reported a revenue of ₹66.74 Lakh, a growth of 15% compared to the previous year. For the same year it recorded a net profit of ₹6.94 Lakh (net margin 10.4%) and EBITDA of ₹9.47 Lakh (EBITDA margin 14.2%).
Company details
Contact details
NCD Immuno-Pharma Private Limited's registered office is in Kolkata, West Bengal. Its e-mail address and telephone number are in the company report.
- Email
- Telephone
- Registered AddressRoom No. 501 5th Floor 'Sri Sai Plaza' Building 89 A.J.C. Bose Road, Kolkata, West Bengal, India – 700014
- IndustryPharma, Drug Formulation & Development
To see the full contact details of NCD Immuno-Pharma Private Limited, buy the company report.
- Company details, directors and signatories
- Historical financials and ratios
- Shareholding pattern and group structure
- Charges with holder and property details
- Legal cases, compliance and MCA filings
Business activity
The main business activity of NCD Immuno-Pharma is human health and social work activities. In detail, this covers human health activities.
| Main activity group code | Main activity | Business activity code | Business activity | Share of turnover |
|---|---|---|---|---|
| Q | Human health and social work activities | 86 | Human health activities |
To see the full business activity and turnover split of NCD Immuno-Pharma Private Limited, buy the company report.
Financials of NCD Immuno-Pharma Private Limited
FY 2025 filings availableNCD Immuno-Pharma Private Limited reported revenue of ₹66.74 Lakh (up 15% YoY) for FY 2025.
Compounded Annual Growth Rate (CAGR)
Revenue rose 15% in the latest year. EBITDA rose 150% in the latest year. All are worked out from the filed statements.
Financial Statement Summary
| Metrics | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 |
|---|---|---|---|---|
| Profit and Loss Statement | ||||
| Revenue from Operations | ||||
| Other Income | ||||
| Total Revenue | ||||
| Cost of Materials Consumed | ||||
| Employee Benefit Expense | ||||
| Finance Costs | ||||
| Depreciation and Amortisation | ||||
| Other Expenses | ||||
| Total Expenses | ||||
| EBITDA | ₹9.47 Lakh | |||
| Profit Before Tax | ||||
| Tax Expense | ||||
| Net Profit (PAT) | ₹6.94 Lakh | |||
| Balance Sheet | ||||
| Share Capital | ||||
| Reserves and Surplus | ||||
| Net Worth (Total Equity) | ||||
| Long-term Borrowings | ||||
| Short-term Borrowings | ||||
| Trade Payables | ||||
| Total Liabilities | ||||
| Fixed Assets | ||||
| Investments | ||||
| Inventories | ||||
| Trade Receivables | ||||
| Cash and Bank Balance | ||||
| Total Assets | ||||
Financial Ratios
| Metrics | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 |
|---|---|---|---|---|
| Profitability | ||||
| EBITDA Margin | 14.2% | |||
| Net Profit Margin | 10.4% | |||
| Return on Equity (ROE) | ||||
| Return on Capital Employed (ROCE) | ||||
| Return on Assets (ROA) | ||||
| Liquidity and Debt | ||||
| Current Ratio | ||||
| Quick Ratio | ||||
| Debt-to-Equity Ratio | ||||
| Interest Coverage Ratio | ||||
| Efficiency and Growth | ||||
| Asset Turnover | ||||
| Receivable Days | ||||
| Payable Days | ||||
| Inventory Days | ||||
| Revenue Growth | ||||
| Net Profit Growth | ||||
To see the full financial statements and ratios of NCD Immuno-Pharma Private Limited, buy the company report.
Board of directors of NCD Immuno-Pharma Private Limited
NCD Immuno-Pharma has 2 directors on record. No former directors are listed.
| Name | Designation | Appointment Date | Tenure | Status |
|---|---|---|---|---|
| Arijit Das | Director | 29 Mar 2022 | 4 Years 7 Months | Current |
| Sandip Kumar Goswami | Managing Director | 29 Mar 2022 | 4 Years 7 Months | Current |
Auditor
NCD Immuno-Pharma Private Limited is audited by AKD & ASSOCIATES for the financial year 2023.
| Auditor firm | Financial year | Firm registration number |
|---|---|---|
| AKD & ASSOCIATES | FY 2023 | 0325223E |
Shareholding
The shareholding of NCD Immuno-Pharma Private Limited is on record for FY 2023, split between promoters, domestic institutions, foreign institutions, public shareholders and others.
| Shareholder category | FY 2023 |
|---|---|
| Promoters | |
| Domestic institutional investors (DII) | |
| Foreign institutional investors (FII) | |
| Public | |
| Others |
To see the full shareholding pattern of NCD Immuno-Pharma Private Limited, buy the company report.
Legal cases
No court or tribunal cases involving NCD Immuno-Pharma Private Limited are on our record; a case search with case numbers, parties and status is in the company report Buy the company report.
MSME payment delays
No delayed payments to MSME suppliers are on our record for NCD Immuno-Pharma Private Limited; the supplier-wise MSME Form 1 check is in the company report Buy the company report.
GST
NCD Immuno-Pharma has 1 GST registration: 1 active.
| GSTIN | State | Status | Registered on |
|---|---|---|---|
| 19AAICN1517G1ZI | West Bengal | Active | 09 Oct 2023 |
To see the full GST registrations and return filing status of NCD Immuno-Pharma Private Limited, buy the company report.
Recent activity
NCD Immuno-Pharma Private Limited has 2 board changes on record since 2022: 2 appointments. The latest: Arijit Das was appointed as Director on 29 Mar 2022.
Frequently asked questions
NCD Immuno-Pharma is an active private limited company based in Kolkata, West Bengal, India. The company works in drug formulation and development, within the pharma industry. It was incorporated on 29 March 2022 (4+ years old) and is registered under CIN U24231WB2022PTC252589.
NCD Immuno-Pharma has 2 current directors:
- Sandip Kumar Goswami - Managing Director
- Arijit Das - Director
The latest financial statements of NCD Immuno-Pharma on record with the MCA are for the year ended 31 March 2025. Its last annual general meeting was held on 30 September 2025. Year-wise statements from FY 2022 are in the company report.
The GSTIN of NCD Immuno-Pharma is 19AAICN1517G1ZI, registered in West Bengal.
The CIN (Corporate Identification Number) of NCD Immuno-Pharma is U24231WB2022PTC252589. It is issued by the Ministry of Corporate Affairs under the Companies Act, 2013, and uniquely identifies the company in India.
NCD Immuno-Pharma was incorporated on 29 March 2022, making it 4+ years old. It is registered with the Registrar of Companies, Kolkata.
Arijit Das was appointed as Director on 29 Mar 2022. Sandip Kumar Goswami was appointed as Managing Director on 29 Mar 2022.
The registered office of NCD Immuno-Pharma is at Room No. 501 5th Floor Sri Sai Plaza Building 89 A.J.C. Bose Road, Kolkata, West Bengal, India – 700014.
NCD Immuno-Pharma operates in the pharma industry, in the drug formulation and development segment.
NCD Immuno-Pharma can be reached at its registered office: Room No. 501 5th Floor Sri Sai Plaza Building 89 A.J.C. Bose Road, Kolkata, West Bengal, India – 700014.

